Johnson & Johnson’s Ollin Biosciences acquisition comes with a Section 3-ready bispecific antibody. The businesses say this eye drug provide benefits over Vabysmo, a Roche drug authorised for moist age-related macular degeneration and diabetic macular edema.
The put up J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Provides Trial Funding appeared first on MedCity Information.
